Microbot Medical has entered into a letter of agreement with Sanmina Corporation to manufacture the Liberty System. The company believes it is necessary to expand its manufacturing capacity to meet expected demand from existing and new accounts as well as to support its cost reduction strategy.

6/16 09:00

Microbot Medical Enters Agreement with Lovell Government Services

Microbot Medical has entered into an agreement with Lovell Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration, a division of the U.S. Department of Veteran Affairs, the Military Health System, which is run by the U.S. Department of Defense, and the U.S. Indian Health Service. Lovell Government Services will become company's Service-Disabled Veteran-Owned Small Business vendor to serve these customers through federal contracting systems.

5/26 08:50

Microbot Medical Receives Israeli Approval for Liberty System

Microbot Medical announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction - and the first outside of the U.S. - to grant marketing clearance for the Liberty System. The regulatory approval from the Israeli Ministry of Health's AMAR Division, the authority responsible for medical device regulation in Israel, allows the Company to market and commercialize the Liberty System in Israel, which also enables the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions. The Company continues to pursue CE Mark certification and is working toward completion by the end of 2026, in preparation for the next phase of commercial expansion into the EU market.

4/13 09:30

Microbot Medical Launches Full Market Release of LIBERTY System in the U.S.

Microbot Medical announced that it has successfully executed its limited market release and will commence the full market release of its LIBERTY endovascular robotic system in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks. The company stated it is showcasing the system at the Society of Interventional Radiology Annual Scientific Meeting to further educate physicians and accelerate market adoption. "We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference," said Harel Gadot, chairman and CEO. "It's exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network."

3/3 09:10

Microbot Medical Ensures Normal Business Operations

Microbot Medical announced that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional. Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquartered in Hingham, MA. This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned. The Company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through its U.S.-based third-party logistics partner to meet anticipated demand.

イベントをもっと見る

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。